Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02141581 · ClinicalTrials.gov registry record · Phase 4

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

A Phase 4 study of Influenza, sponsored by Stanford University.

Completed
Registry status
Phase 4
Development phase
86
Enrollment target
1
Study location

NCT02141581: Completed Phase 4 study of Influenza, sponsored by Stanford University.

NCT02141581 is a Phase 4 study of Influenza that has completed, run by Stanford University. The registered enrollment target is 86 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02141581, a Phase 4 study of Influenza, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 4
Development phase
86 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.

Conditions Studied

Interventions

  • BIOLOGICAL Fluzone® (IM)
  • BIOLOGICAL Fluzone® Intradermal (ID)
  • BIOLOGICAL 2011-2012 FluMist®

Study Locations (1)

California

  • Stanford LPCH Vaccine Program - Stanford

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2011-08
Est. Completion 2014-12
Phase Phase 4
Stanford University

1,744 total trials

What the finished NCT02141581 record still lists

NCT02141581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Fluzone® (IM) is the first listed.

NCT02141581 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02141581 about?

NCT02141581 is a clinical study titled "Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)". The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy...

What is the current status of trial NCT02141581?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2011-08. Estimated completion is 2014-12.

What conditions does trial NCT02141581 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT02141581?

The interventions under investigation include: Fluzone® (IM) (BIOLOGICAL), Fluzone® Intradermal (ID) (BIOLOGICAL), 2011-2012 FluMist® (BIOLOGICAL).

Who is sponsoring clinical trial NCT02141581?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02141581 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02141581's enrollment target sits among peer trials

86 109th of 156 higher than 48 of 156 other Influenza trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02141581, the US trial registry maintained by the National Library of Medicine. NCT02141581 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.